- Home
- RYAN vs QGEN Comparison
RYAN vs QGEN Comparison
Compare RYAN & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYAN
- QGEN
- Stock Information
- Founded
- RYAN 2010
- QGEN 1986
- Country
- RYAN United States
- QGEN Netherlands
- Employees
- RYAN N/A
- QGEN N/A
- Industry
- RYAN Specialty Insurers
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RYAN Finance
- QGEN Health Care
- Exchange
- RYAN Nasdaq
- QGEN Nasdaq
- Market Cap
- RYAN 8.8B
- QGEN 9.1B
- IPO Year
- RYAN 2021
- QGEN 1996
- Fundamental
- Price
- RYAN $67.64
- QGEN $48.02
- Analyst Decision
- RYAN Buy
- QGEN Buy
- Analyst Count
- RYAN 13
- QGEN 9
- Target Price
- RYAN $74.36
- QGEN $50.79
- AVG Volume (30 Days)
- RYAN 876.3K
- QGEN 1.3M
- Earning Date
- RYAN 07-31-2025
- QGEN 07-30-2025
- Dividend Yield
- RYAN 0.71%
- QGEN 3.15%
- EPS Growth
- RYAN N/A
- QGEN N/A
- EPS
- RYAN 0.27
- QGEN 0.42
- Revenue
- RYAN $2,593,912,000.00
- QGEN $2,002,874,000.00
- Revenue This Year
- RYAN $27.75
- QGEN $6.36
- Revenue Next Year
- RYAN $15.43
- QGEN $6.18
- P/E Ratio
- RYAN $250.29
- QGEN $113.60
- Revenue Growth
- RYAN 22.53
- QGEN 3.31
- 52 Week Low
- RYAN $55.67
- QGEN $37.63
- 52 Week High
- RYAN $77.16
- QGEN $48.36
- Technical
- Relative Strength Index (RSI)
- RYAN 47.01
- QGEN 71.53
- Support Level
- RYAN $63.90
- QGEN $46.37
- Resistance Level
- RYAN $69.49
- QGEN $46.83
- Average True Range (ATR)
- RYAN 1.69
- QGEN 0.69
- MACD
- RYAN 0.13
- QGEN -0.00
- Stochastic Oscillator
- RYAN 54.24
- QGEN 89.25
About RYAN Ryan Specialty Holdings Inc.
Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).